EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Factors associated with lenvatinib adherence in thyroid cancer and hepatocellular carcinoma

Yoshikazu Tateai iD, Kazuyoshi Kawakami iD, Minori Teramae, Naoki Fukuda, Takashi Yokokawa, Kazuo Kobayashi iD, Naoki Shibata, Wataru Suzuki, Hisanori Shimizu, Shunji Takahashi, Masato Ozaka, Naoki Sasahira und 2 weitere

PLOS ONE · 2023

DOI: 10.1371/journal.pone.0294320 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS ONE, 2023. Verfasst von Yoshikazu Tateai und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Thyroid Neoplasms, Quinolines. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Lenvatinib is an oral anticancer medication used to treat radioiodine-refractory thyroid cancer and unresectable hepatocellular carcinoma. The purpose of this study is to evaluate lenvatinib adherence by patients and to identify factors associated with decreased lenvatinib adherence.

Methods

Among 153 patients who started treatment with lenvatinib for unresectable thyroid cancer or unresectable hepatocellular carcinoma between May 1, 2015 and August 31 2021 at the Cancer Institute Hospital of the Japanese Foundation for Cancer Research, 102 were eligible for this study (55 thyroid cancer, 47 hepatocellular carcinoma). The lenvatinib adherence rate in a treatment cycle was defined as the number of times a patient took lenvatinib in a 28-day cycle divided by the prescribed 28 doses. The rate was determined by pill counting and self-reporting at the pharmaceutical outpatient clinic. Reasons for non-adherence were established by interview and analyzed.

Results

The median adherence rate of lenvatinib in the first cycle was 90.1% (n = 55) in thyroid cancer and 94.9% (n = 47) in hepatocellular carcinoma. In thyroid cancer, there were 255 incidents of lenvatinib non-adherence. Non-adherence was mainly associated with bleeding events (18.6%), followed by hand-foot skin reactions (10.6%). In hepatocellular carcinoma, there were 97 incidents of non-adherence. Hypertension accounted for 20.6%, followed by hoarseness (18.6%) and diarrhea (17.5%).

Conclusion

The adherence rate for lenvatinib in Japanese patients with thyroid and hepatocellular carcinoma in real-world clinical practice was more than 90% in this study. Hypertension was a major reason for non-adherence, followed by hand-foot skin reactions and diarrhea.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsThyroid NeoplasmsQuinolinesHypertensionAntineoplastic AgentsHumansIodine RadioisotopesPhenylurea CompoundsDiarrhea

Substanzen

lenvatinibIodine RadioisotopesPhenylurea CompoundsQuinolinesAntineoplastic Agents

Autor:innen und Institutionen

  • Department of Pharmacy, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.
  • Division of Drug Informatics, Keio University Faculty of Pharmacy, Tokyo, Japan.
  • Department of Medical Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.
  • Department of Hepato-Biliary-Pancreatic Medicine, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.

ORCID-Profile: Yoshikazu Tateai, Kazuyoshi Kawakami, Kazuo Kobayashi, Satoko Hori

Zitieren

APA

Tateai, Y., Kawakami, K., Teramae, M., Fukuda, N., Yokokawa, T., Kobayashi, K., Shibata, N., Suzuki, W., Shimizu, H., Takahashi, S., Ozaka, M., Sasahira, N., Hori, S., & Yamaguchi, M. (2023). Factors associated with lenvatinib adherence in thyroid cancer and hepatocellular carcinoma. PLOS ONE. https://doi.org/10.1371/journal.pone.0294320

Vancouver

Tateai Y, Kawakami K, Teramae M, Fukuda N, Yokokawa T, Kobayashi K, et al. Factors associated with lenvatinib adherence in thyroid cancer and hepatocellular carcinoma. PLOS ONE. 2023. doi:10.1371/journal.pone.0294320

BibTeX
@article{Tateai2023,
  author = {Tateai, Yoshikazu and Kawakami, Kazuyoshi and Teramae, Minori and Fukuda, Naoki and Yokokawa, Takashi and Kobayashi, Kazuo and Shibata, Naoki and Suzuki, Wataru and Shimizu, Hisanori and Takahashi, Shunji and Ozaka, Masato and Sasahira, Naoki and Hori, Satoko and Yamaguchi, Masakazu},
  title = {Factors associated with lenvatinib adherence in thyroid cancer and hepatocellular carcinoma},
  journal = {PLOS ONE},
  year = {2023},
  doi = {10.1371/journal.pone.0294320}
}
Kostenlos starten →